Cyclin-dependent kinase 4 (CDK4) and CDK6 are critical mediators of cellular transition into S phase and are important for the initiation, growth and survival of many cancer types. Pharmacological inhibitors of CDK4/6 have rapidly become a new standard of care for patients with advanced hormone...
Dysregulation of cyclin-dependent kinase (CDK)4 and CDK6 by gain of function or loss ofinhibition is common in human cancer including multiple myeloma, but success in targeting CDK with broad-spectrum inhibitors has been modest. By selective and reversible inhibition ofCDK4/CDK6, we have develop...
activity, which promotes phosphorylation of Rb, can occur through several mechanisms, including overexpression of D-type cyclins, mutation or amplification of CDK4/6, or loss of cyclin D-CDK4/6 negative regulators such as p16INK4A [1], [2], [3], and ultimately leads to cancer cell ...
Targeting CDK4 and CDK6 in cancer Article 18 March 2022 Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2 Article Open access 07 June 2021 Targeting cyclin-dependent kinase 9 in cancer therapy Article 22 November 2021 Referen...
targeted therapies, immunotherapy, or classical chemotherapy to improve future therapeutic uses of CDK4/6 inhibition in a variety of cancers in clinical ... S Shi - 《Transactions on Cancer》 被引量: 0发表: 2023年 Enhancing immunogenic responses through CDK4/6 and HIF2α inhibition in Merkel ...
Despite the large number of CDKs and cyclins, only a few have been strongly implicated in breast cancer pathogenesis. This review focuses primarily on CDK4 and CDK6, which have largely overlapping though not entirely identical specificity, as well as cyclin D1, the most characterized member of...
) are the proteins encoded by two splice variants of the same gene, and members of the MAPK superfamily also include ERK3/4, ERK5, ERK7/8, Jun N-terminal kinase (JNK)1/2/3 and p38, α, β and γ (ERK6) and δ15, 16, all of which have been shown to play roles in cancer....
Ectopic over-expression of miR-506 in ovarian cancer cells was sufficient to inhibit proliferation and to promote senescence. We also demonstrated that CDK4 and CDK6 are direct targets of miR-506, and that miR-506 can inhibit CDK4/6–FOXM1 signalling, which is activated in the majority of ...
Inflammation has accompanied human beings since the emergence of wounds and infections. In the past decades, numerous efforts have been undertaken to explore the potential role of inflammation in cancer, from tumor development, invasion, and metastasis to the resistance of tumors to treatment. Inflamma...
CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy have shown impressive efficacy in estrogen receptor-positive advanced breast cancer. However, most patients will eventually experience disease progression on this combination, underscoring the n